Literature DB >> 35986133

Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study.

Bertha Alejandra Martinez-Cannon1, Enrique Soto-Perez-de-Celis2, Aura Erazo Valle-Solis3, Claudia Arce-Salinas4, Enrique Bargallo-Rocha4, Veronica Bautista-Piña5, Guadalupe Cervantes-Sanchez6, Christian Haydeé Flores-Balcázar7, Maria Del Carmen Lara Tamburrino8, Ana Lluch9, Antonio Maffuz-Aziz10, Victor Manuel Pérez-Sánchez11, Adela Poitevin-Chacón12, Efraín Salas-González13, Laura Torrecillas Torres6, Vicente Valero14, Yolanda Villaseñor-Navarro15, Jesús Cárdenas-Sánchez16.   

Abstract

BACKGROUND: Adherence to clinical practice guidelines improves outcomes for patients with breast cancer. However, their implementation may not be feasible in low- and middle-income countries. This study aimed to evaluate physicians' adherence, attitudes, and barriers towards the Colima Consensus, which is the Mexican national breast cancer clinical practice guideline.
METHODS: A cross-sectional, 31-item survey was e-mailed to Consensus attendees and members of the Mexican Society of Oncology and Mexican Mastology Association. Descriptive statistics, univariate, and multivariate analysis were used to analyze the associations between participants' characteristics, adherence, attitudes, and barriers.
RESULTS: Of 439 respondents, 78% percent adhered to Consensus recommendations and 94% believed it was applicable to their clinical practice. Forty percent reported using the Consensus as their sole breast cancer guideline. This was associated with being a surgical oncologist (OR 3.3, 95% CI 2.0-5.3) and practicing at a public hospital (OR 2.1, 95% CI 1.2-3.7). The most common barriers to adherence were lack of resources and logistical problems. Regarding attitudes towards the Consensus, 90% considered it a good educational tool, 89% considered it a reliable source of information, and 90% thought it improved quality of care.
CONCLUSIONS: We showed high levels of adherence and positive attitudes towards the Colima Consensus, with a significant proportion of physicians using it as their only guideline. Lack of resources and logistical issues were the main barriers to adherence. Our results highlight the relevance of local breast cancer guidelines and suggest a need for the creation of resource-stratified guidelines.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Adherence; Breast cancer; Clinical practice guidelines; Limited-resource settings; Low- and middle-income countries

Year:  2022        PMID: 35986133     DOI: 10.1007/s12094-022-02921-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  24 in total

Review 1.  Improving outcomes in breast cancer for low and middle income countries.

Authors:  C H Yip; I Buccimazza; M Hartman; S V S Deo; P S Y Cheung
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

2.  Adherence to cancer treatment guidelines: influence of general and cancer-specific guideline characteristics.

Authors:  Marianne J Heins; Judith D de Jong; Inge Spronk; Vincent K Y Ho; Mirian Brink; Joke C Korevaar
Journal:  Eur J Public Health       Date:  2017-08-01       Impact factor: 3.367

3.  Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach.

Authors:  Anita Andreano; Paola Rebora; Maria Grazia Valsecchi; Antonio Giampiero Russo
Journal:  Breast Cancer Res Treat       Date:  2017-04-01       Impact factor: 4.872

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis.

Authors:  W van de Water; E Bastiaannet; O M Dekkers; A J M de Craen; R G J Westendorp; A C Voogd; C J H van de Velde; G J Liefers
Journal:  Br J Surg       Date:  2012-04-11       Impact factor: 6.939

Review 6.  Breast cancer in Mexico: a growing challenge to health and the health system.

Authors:  Yanin Chávarri-Guerra; Cynthia Villarreal-Garza; Pedro E R Liedke; Felicia Knaul; Alejandro Mohar; Dianne M Finkelstein; Paul E Goss
Journal:  Lancet Oncol       Date:  2012-08       Impact factor: 41.316

7.  Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.

Authors:  Bénédicte Poncet; Cyrille Colin; Thomas Bachelot; Isabelle Jaisson-Hot; Laure Derain; Laurent Magaud; Cécile Fournel-Federico; Mireille Mousseau; Jean-Dominique Tigaud; Jean-Philippe Jacquin; Véronique Trillet-Lenoir
Journal:  Am J Clin Oncol       Date:  2009-08       Impact factor: 2.339

8.  Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study.

Authors:  Achim Wöckel; Dominic Varga; Ziad Atassi; Christian Kurzeder; Regine Wolters; Manfred Wischnewsky; Christine Wulff; Rolf Kreienberg
Journal:  Onkologie       Date:  2010-01-22

9.  Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature.

Authors:  Mia Bierbaum; Frances Rapport; Gaston Arnolda; Brona Nic Giolla Easpaig; Klay Lamprell; Karen Hutchinson; Geoff P Delaney; Winston Liauw; Richard Kefford; Ian Olver; Jeffrey Braithwaite
Journal:  Implement Sci       Date:  2020-05-27       Impact factor: 7.327

10.  Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries.

Authors:  Ignacio Ricci-Cabello; Adrián Vásquez-Mejía; Carlos Canelo-Aybar; Ena Niño de Guzman; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Ivan Solà; Yang Song; Luciana Neamtiu; Elena Parmelli; Zuleika Saz-Parkinson; Pablo Alonso-Coello
Journal:  BMC Health Serv Res       Date:  2020-10-07       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.